Elanix Biotechnologies is a tissue regeneration company. We develop and commercialize products for acute wound care, dermatological and gynecological applications, as well as providing cell technology services.
The company was founded in 2012 as a spin-off from the University Hospital of Lausanne (CHUV), Switzerland, to commercialize a patented progenitor cell technology. Progenitor cells are fully differentiated yet immunologically neutral cells that are very potent inducers of tissue growth and healing. Elanix owns GMP certified Master and Working cell banks containing vast quantities of cells.
The Company is headquartered in Epalinges, Switzerland with offices in Hamburg and listed on the Frankfurt stock exchange under the symbol ELN.
c/o Frankfurt Hanauer Landstraße BC GmbH / Hanauer Landstraße 291 B, 60314 Frankfurt – Germany
Dec. 1, 2015Designated Sponsor(s)
mwb fairtrade Wertpapierhandelbank AGStock exchange(s)
Frankfurt Stock Exchange